BriaCell Therapeutics Corp.

Nasdaq:BCTXNasdaq:BCTXLNasdaq:BCTXWNasdaq:BCTXZ

Pharmaceutical Preparations·WEST VANCOUVER, A1

CEO

Williams William V.

Summary Financials

Revenue

—

Adj. EBITDA

-$33.3M

FY 2025

Net Income

-$4.8M

FY 2025

EPS (Diluted)

-$43.68

FY 2025

Stock Price

$3.86

-4.0%

2026-03-06

52W Range

$3.60 – $98.20

P/E Ratio

-0.1x

Market Cap

$7.3M

Cash

$862,089

FY 2025

Total Debt

—

Net Cash

$862,089

Enterprise Value

$6.4M

Debt / EBITDA

0.0x

FY 2025

EV / EBITDA

-0.2x

Employees

—

Revenue

—

Adj. EBITDA

-$33.3M

FY 2025

Net Income

-$4.8M

FY 2025

EPS (Diluted)

-$43.68

FY 2025

Stock Price

$3.86

-4.0%

2026-03-06

52W Range

$3.60 – $98.20

P/E Ratio

-0.1x

Market Cap

$7.3M

Cash

$862,089

FY 2025

Total Debt

—

Net Cash

$862,089

Enterprise Value

$6.4M

Debt / EBITDA

0.0x

FY 2025

EV / EBITDA

-0.2x

Employees

—